Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

2.13p
   
  • Change Today:
    -0.055p
  • 52 Week High: 3.42p
  • 52 Week Low: 0.85p
  • Currency: UK Pounds
  • Shares Issued: 416.44m
  • Volume: 2,365,381
  • Market Cap: £8.85m
  • RiskGrade: 328

ImmuPharma making final preparations for Lupuzor phase 3 trial

By Josh White

Date: Wednesday 04 May 2022

LONDON (ShareCast) - (Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.
The AIM-traded firm said that, further to the recent positive results from the pharmacokinetic study announced in April, its US partner Avion Pharmaceuticals was now requesting final guidance from the US Food and Drug Administration (FDA) to start the phase 3 trial.

It said the pharmacokinetic study, required by the FDA, demonstrated that the key endpoints had been met, and that P140 was safe and well tolerated across all doses and in all subjects in-line with all human dosing to date.

"We are delighted to be announcing positive progress towards the commencement of the new optimised international phase 3 trial of Lupuzor in lupus patients," said chief executive officer Tim McCarthy.

"Following the positive readout from the pharmacokinetic study, we have been working closely with the team at Avion to move Lupuzor as quickly as possible to the start of the phase 3 trial."

At 1221 BST, shares in ImmuPharma were up 4.04% at 6.7p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 2.13p
Change Today -0.055p
% Change -2.52 %
52 Week High 3.42p
52 Week Low 0.85p
Volume 2,365,381
Shares Issued 416.44m
Market Cap £8.85m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average64.42% below the market average
18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average18.52% below the sector average
Price Trend
4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average4.00% above the market average
47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average47.37% above the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:17 14,000 @ 2.08p
16:13 22,386 @ 2.20p
16:13 9,454 @ 2.20p
16:13 10,000 @ 2.15p
16:12 15,000 @ 2.15p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page